Literature DB >> 1908134

Relative costs and cost-effectiveness of extracorporeal shock-wave lithotripsy versus percutaneous nephrolithotomy in the treatment of renal and ureteric stones.

N Mays1.   

Abstract

This paper presents empirical data from the United Kingdom National Health Service on the comparative mean hospital costs per patient of first generation extracorporeal shock wave lithotripsy (ESWL) and percutaneous nephrolithotomy (PCN) in the treatment of kidney stones. These results were subjected to a sensitivity analysis and related to evidence on the health effects of the two approaches to treatment. The hospital costs of PCN were found to be lower than for ESWL in the empirical comparison and in most but not all the scenarios developed in the sensitivity analysis. The direction of the comparison was reversed when a high throughput was assumed for ESWL and a significantly higher per diem cost for PCN than ESWL. The relative cost-effectiveness of the two modes of treatment depended on whether successful treatment was defined in terms of rendering the patient free of stones (the traditional endpoint of treatment) or the rate at which patients returned to their normal activities.

Entities:  

Mesh:

Year:  1991        PMID: 1908134     DOI: 10.1016/0277-9536(91)90201-m

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  3 in total

Review 1.  A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research.

Authors:  R T Anderson; N K Aaronson; M Bullinger; W L McBee
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 2.  Critical review of the international assessments of health-related quality of life.

Authors:  R T Anderson; N K Aaronson; D Wilkin
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

3.  How has extracorporeal shock-wave lithotripsy changed the treatment of urinary stones in Quebec?

Authors:  A R Levy; M McGregor
Journal:  CMAJ       Date:  1995-12-15       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.